Evommune Inc

Research Evommune Inc (EVMN) on Bullrun: market cap USD 542.08M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerEVMN
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 542.08M
• Financial periodFY2025
• RevenueUSD 13.00M
• Revenue growth85.7%
• Net income-USD 68.87M
• Free cash flow-USD 76.68M

Valuation Snapshot

latest market cap is USD 542.08M.

About Evommune Inc

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Frequently asked questions

What is Evommune Inc's market cap?

Evommune Inc's market capitalization is USD 542.08M.

What does Evommune Inc do?

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative...